Clare Grieve

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

Anita Kumar, Carla Casulo, Ranjana H. Advani et al. · Journal of Clinical Oncology · 2021 · 57 citations · Full text

Medicine, Nuclear Medicine, Oncology +13

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a <i>TP53</i> mutation

Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson et al. · Blood · 2024 · 48 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, <i>TP53</i>-Mutant Mantle Cell Lymphoma

Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson et al. · Blood · 2023 · 27 citations

Medicine, Hematology, Oncology +10

LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX (BOVEN) IN PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL

Jacob D. Soumerai, Ahmet Doǧan, Venkatraman Seshan et al. · Hematological Oncology · 2023 · 17 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Anita Kumar, Jacob D. Soumerai, Jeremy S. Abramson et al. · Blood · 2021 · 16 citations

Medicine, Oncology, Pharmacology +14